Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (11835)	11/28/1997 11:40:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

TD, The ENMD news sounds exciting and the street is clearly buying today. Inhibition of angiogenesis of course is not new. That's the mechanism of BBIOY's Maristat (sp?) and it is in advanced trials for several cancers. AGPH also has an MMPI program (with Roche?) as does LGND. LGND hasn't said much about their program lately, so I'm not sure on the progress (I think that the lack of progress is related to bioavailablity). I'm not sure about the resistance angle. Of course there would not be selection in the patient against the angiogenesis inhibition, but tumors that could survive with a diminished blood supply would create a positive selection pressure. I haven't check out Jesse Eisinger's article yet and am getting ready to go to yet another soccer tournament (indoor in Erie).